This randomized, double-blind, placebo-controlled Phase III trial was designed to test the efficacy ... of-study biopsy if serum PSA levels fell within a prespecified range. Prostate cancer ...
IRVINE, Calif. - Biomerica, Inc. (NASDAQ:BMRA), a diagnostic solutions provider with a market capitalization of $6.4 million and showing a notable 16.6% year-to-date stock return, has received ...
PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate Cancer- Prostate Cancer: The ...
Biomerica (BMRA) announced that its Fortel Prostate Specific Antigen Screening Test has received approval from the United Arab Emirates ...